Biocardia Net Income from 2010 to 2026

BCDA Stock  USD 1.23  0.03  2.38%   
Biocardia's Net Loss is decreasing over the years with slightly volatile fluctuation. Overall, Net Loss is projected to go to about -6.8 M this year. From 2010 to 2026 Biocardia Net Loss quarterly data regression line had arithmetic mean of (6,684,508) and significance of  0. View All Fundamentals
 
Net Loss  
First Reported
1997-03-31
Previous Quarter
-2 M
Current Value
-1.5 M
Quarterly Volatility
2.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Biocardia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocardia's main balance sheet or income statement drivers, such as Depreciation And Amortization of 73.2 K, Interest Expense of 6.6 K or Selling General Administrative of 3.3 M, as well as many indicators such as Price To Sales Ratio of 231, Dividend Yield of 0.03 or PTB Ratio of 6.75. Biocardia financial statements analysis is a perfect complement when working with Biocardia Valuation or Volatility modules.
  
Build AI portfolio with Biocardia Stock
Check out the analysis of Biocardia Correlation against competitors.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.
Analyzing Biocardia's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Biocardia's current valuation and future prospects.

Latest Biocardia's Net Income Growth Pattern

Below is the plot of the Net Income of Biocardia over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Biocardia financial statement analysis. It represents the amount of money remaining after all of Biocardia operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Biocardia's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biocardia's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (7.95 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Biocardia Net Income Regression Statistics

Arithmetic Mean(6,684,508)
Coefficient Of Variation(107.39)
Mean Deviation5,974,664
Median(7,946,000)
Standard Deviation7,178,301
Sample Variance51.5T
Range24.7M
R-Value(0.65)
Mean Square Error31.4T
R-Squared0.43
Significance0
Slope(930,861)
Total Sum of Squares824.4T

Biocardia Net Income History

2026-6.8 M
2025-7.2 M
2024-7.9 M
2023-11.6 M
2022-11.9 M
2021-12.6 M
2020-15 M

Other Fundumenentals of Biocardia

Biocardia Net Income component correlations

About Biocardia Financial Statements

Biocardia stakeholders use historical fundamental indicators, such as Biocardia's Net Income, to determine how well the company is positioned to perform in the future. Although Biocardia investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biocardia's assets and liabilities are reflected in the revenues and expenses on Biocardia's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biocardia. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-7.2 M-6.8 M
Net Loss-7.2 M-7.5 M
Net Loss-10.7 M-11.3 M
Net Loss(2.61)(2.74)
Net Income Per E B T 1.15  1.29 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:
Check out the analysis of Biocardia Correlation against competitors.
For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. Projected growth potential of Biocardia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biocardia assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.42)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.86)
Return On Equity
(3.17)
Understanding Biocardia requires distinguishing between market price and book value, where the latter reflects Biocardia's accounting equity. The concept of intrinsic value—what Biocardia's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biocardia's price substantially above or below its fundamental value.
It's important to distinguish between Biocardia's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biocardia should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biocardia's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.